Mercury Laboratories Limited (BOM:538964)

Market Cap	1.04B
Revenue (ttm)	751.01M
Net Income (ttm)	31.45M
Shares Out	1.20M
EPS (ttm)	26.21
PE Ratio	33.14
Forward PE	n/a
Dividend	3.50 (0.40%)
Ex-Dividend Date	Aug 6, 2025

Volume	3
Average Volume	194
Open	868.55
Previous Close	868.55
Day's Range	868.55 - 868.55
52-Week Range	736.00 - 1,190.00
Beta	0.63
RSI	52.13
Earnings Date	Aug 7, 2025

About Verve Therapeutics

Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergi...

• Industry: Pharmaceutical Preparations
• Founded: 1962
• Employees: 503
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 538964

Financial Performance

In 2024, Mercury Laboratories's revenue was 751.01 million, a decrease of -0.61% compared to the previous year's 755.59 million. Earnings were 31.45 million, a decrease of -44.38%.